Drugs / Hemay022
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04673474 | Dec 2020 → Feb 2021 | — | Tianjin Hemay Oncology Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT03308201 | Oct 2017 → Jun 2022 | breast cancer | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02476539 | Oct 2015 → Sep 2023 | HER2 positive breast carcinoma | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06313983 | Jan 2022 → Dec 2025 overdue | breast cancer | Tianjin Hemay Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hemay022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02476539 ↗ |
| Action | Inhibit | “the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay022” NCT02476539 ↗1“Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL3545111 ↗ |
| Modality | Small molecule | “Hemay022 is a novel small-molecule” PMID 38455366 ↗ Feb 2024 |
| Route | Oral | “Hemay022 administered once daily by mouth for 28 days” NCT02476539 ↗ |
| Target | EGFR | “the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay022” NCT02476539 ↗ |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL3545111 ↗ |